Just a few months after Immune Design saw its shares crater on a phase II fail, Merck & Co/MSD has agreed a deal to acquire the biotech and its immuno-oncology and vaccines pipeline.
Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a pr
The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol
As part of a series of articles highlighting the role of women in the pharma industry, Richard Staines speaks to Louise Houson, MSD’s managing director for UK and Ireland
Sanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting a green light for their six-in-one paediatric shot Vaxelis.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
